Growth Hormone Research: From CJC-1295 to MK-677, Ipamorelin, Exogenous GH and IGF-1

Growth hormone is secreted in pulses, not continuously. The pituitary sends out discrete bursts of GH across the day, with the largest surge during deep sleep. These pulses vary in amplitude (how tall they are) and frequency (how often they occur). Together, amplitude and frequency define GH’s physiologic rhythm. Research into GH-related compounds ultimately comes down to modulating one or both of these levers—while preserving physiology rather than disrupting it.

In this in-depth article we will explore:

• CJC-1295: the amplitude driver
• MK-677: the oral ghrelin mimetic with baggage
• Ipamorelin: the clean frequency driver
• Exogenous GH: powerful but blunt
• IGF-1: targeted growth factor
• SARMs: why they don’t belong in this discussion
• Designing sustainable GH-axis research
• Frequently asked questions

How GH secretion is controlled

The hypothalamus and pituitary coordinate three signals. Growth hormone–releasing hormone primes the pituitary and mainly determines pulse height. Ghrelin signalling through the GH secretagogue receptor increases the probability of a pulse and therefore frequency. Somatostatin provides the braking force that suppresses pulses between surges. Approaches that work with this architecture tend to produce cleaner, more interpretable outcomes than approaches that flatten or fight it.

GHRH vs GHRP vs ghrelin mimetic

GHRH analogues increase pulse height. GHRPs increase pulse frequency via the ghrelin receptor using short, placeable signals. Ghrelin mimetics also act through the ghrelin receptor but are small molecules with long exposure and an almost continual drive. At a practical level, the first two preserve pulsatility when timed well; the third can blur it.

CJC-1295: the amplitude driver

CJC-1295 with DAC and CJC-1295 without DAC are GHRH analogues. Their role is to increase the height of each GH pulse. They act at the pituitary GHRH receptor, amplifying bursts without creating new ones.

There are two main formats:

• With DAC (Drug Affinity Complex): very long half-life, meaning less frequent administration but less alignment with physiologic pulsatility.
• Without DAC (Modified GRF 1-29): short half-life, allowing precise timing with the body’s natural GH surges, especially nocturnal ones.

Researchers value CJC-1295 for its clean, predictable profile and its ability to elevate GH and IGF-1 in a pattern that still respects physiology. On its own it raises amplitude but does not change frequency.

MK-677: frequency with baggage

MK-677, or ibutamoren, is an oral ghrelin receptor agonist. Mechanistically, it behaves like a GHRP: it increases the likelihood and frequency of GH pulses. Its oral availability and long half-life (around 24 hours) make it popular on paper. Stacking MK-677 with CJC looks logical: one increases amplitude, the other frequency.

The problem is the trade-offs:

• Appetite stimulation: as a ghrelin mimetic, MK-677 can drive hunger dramatically, derailing fat-loss studies.
• Water retention and oedema: leading to bloating and higher blood pressure.
• Lipid changes: reduced HDL, sometimes higher LDL.
• Liver stress: elevations in AST/ALT.
• Kidney markers: rises in creatinine and altered renal profile.
• Insulin resistance: worsened fasting glucose and HbA1c.
• “Always-on” drive: the long half-life means the pituitary never rests, risking receptor desensitisation.

Short-term results often include water-driven fullness, appetite-driven mass gain, and higher IGF-1. But when exposure stops, most of these changes fade quickly. Mechanistically, CJC plus MK-677 is viable. Strategically, it is poor. This is why we do not and will not supply MK-677.

Ipamorelin: clean, selective frequency

Ipamorelin is a short-acting, selective GHRP. Like MK-677 it signals via the ghrelin receptor, but it does so briefly and cleanly. It does not significantly raise prolactin or cortisol, which were issues with older GHRPs such as GHRP-6 and hexarelin.

Because it is short-acting, Ipamorelin can be administered at physiologically appropriate times, such as before sleep, reinforcing the body’s largest natural GH pulse. It raises frequency without flattening pulsatility. When paired with CJC-1295, the result is taller pulses that occur more often, while still respecting physiology. This combination is often referred to as the classic GH secretagogue stack.

Exogenous GH: powerful but blunt

Exogenous GH is often held up as the “gold standard,” but its action is blunt compared to peptides. Instead of pulsatile secretion, exogenous GH delivers a flat, continuous exposure. At first this looks effective: more GH equals more IGF-1. But constant exposure comes at a cost.

Tissue sensitivity and desensitisation

Receptors are designed to see pulses: stimulation followed by recovery. With exogenous GH, receptors are bathed constantly. Over time they adapt by downregulating or desensitising, making tissues less responsive. This means progressively higher doses are required for diminishing returns. This “blunting” is why many long-term GH users escalate dosing and side effects together.

Organ growth explained (heart, liver, kidney, connective tissue)

Continuous GH raises IGF-1 output from the liver around the clock. IGF-1 is a systemic growth signal that acts on many tissues, not just muscle. With persistent exposure, multiple organs can enlarge beyond physiologic norms:

• Heart (cardiac hypertrophy): the heart muscle can thicken, with chronic thickening the walls stiffen, diastolic filling worsens, and long-term cardiovascular risk rises.
• Liver (hepatomegaly): a larger liver increases metabolic demand and can predispose to fatty infiltration or fibrosis over time.
• Kidneys (renal hypertrophy): Sustained enlargement raises metabolic strain and may accelerate decline in vulnerable individuals.
• Connective/soft tissue: swelling and overgrowth in fascia and synovial spaces contributes to carpal tunnel symptoms; skin, hands, feet, and jaw can thicken in acromegaly-like patterns at higher/longer exposures.

This is why a blunt, non-pulsatile GH signal is problematic: it does not just grow muscle — it pushes growth signals everywhere, continuously. By contrast, secretagogues such as CJC-1295 and Ipamorelin reinforce pulses, so receptors experience stimulation and recovery cycles that preserve sensitivity and limit systemic overgrowth pressure.

The side-effect profile

• Water retention and oedema
• Carpal tunnel symptoms
• Insulin resistance and impaired glucose tolerance
• Organ and tissue enlargement with prolonged high doses (as detailed above)
• Constantly high IGF-1 from hepatic conversion, raising concerns about non-specific growth signalling

In short, exogenous GH is a blunt tool. It delivers force, but without finesse, and with a side-effect battery that can outweigh its benefits.

IGF-1: precision growth

Much of GH’s effect is mediated through insulin-like growth factor 1 (IGF-1), produced mainly in the liver. Exogenous GH raises IGF-1 systemically, everywhere. By contrast, IGF-1 can be administered directly in research, with the option for local or site-specific effects.

IGF-1, especially IGF-1 LR3, can act locally at the site of administration, providing targeted growth and repair. This is fundamentally different from GH’s blunt systemic effect. Researchers can therefore explore highly specific outcomes—muscle growth at a trained site, or tissue repair—without globally elevating IGF-1 to the same extent.

When combined with CJC-1295 and Ipamorelin, the stack becomes powerful and precise: natural GH pulsatility is enhanced (amplitude and frequency), while IGF-1 provides local, targeted growth. This respects physiology and reduces collateral side effects.

A note on SARMs

SARMs are sometimes compared to peptides, but they do not belong in this discussion. They act at the androgen receptor, not the GH axis. Their profile includes androgen suppression, liver stress, adverse lipid shifts, and blood pressure issues. They are not GH modulators and are the wrong tool for research into pulsatility or tissue repair.

Designing sustainable GH-axis research

Good design asks three questions:

1. Does the protocol respect natural pulsatility?
2. Does it minimise confounders such as water, appetite, and metabolic strain?
3. Do the observed effects persist when exposure ends?

By those measures:

• CJC-1295 + MK-677: Yes, it works. But appetite, water, lipids, and insulin resistance make it unsustainable.
• Exogenous GH: Powerful, but blunt. Side effects and tissue desensitisation climb with exposure.
• SARMs: Not in the same category; androgen risks with no role in GH modulation.
• CJC-1295 + Ipamorelin: Clean, physiologic, sustainable. Add IGF-1 for targeted growth. This is the smart stack.

Frequently asked questions

Do you need PCT after MK-677?

No. MK-677 is not an androgen and does not suppress the HPTA. When discontinued, GH and IGF-1 return to baseline. What people often call “shutdown” is simply the loss of water, appetite, and elevated IGF-1. Lipids, glucose, and organ labs should still be monitored.

Which CJC format is better?

With DAC for convenience and fewer administrations. Without DAC (Modified GRF 1-29) for short action that can be aligned with sleep and natural pulses.

Why not older GHRPs like GHRP-6 or hexarelin?

They work, but are less selective, often raising prolactin and cortisol or spiking appetite. Ipamorelin is cleaner.

Can GH and peptides be combined?

It is possible, but redundant. GH is blunt and constant; peptides are pulse-driven and physiologic. If precision and sustainability are the goal, peptides and IGF-1 are the smarter approach.

Final stance

CJC-1295 is the amplitude lever. Ipamorelin is the frequency lever. MK-677 is viable but strategically poor. Exogenous GH is powerful but blunt, driving tissue desensitisation and organ growth across heart, liver, kidneys and connective tissues. SARMs are not GH modulators at all. The coherent, physiologic, and sustainable choice for GH-axis research is CJC-1295 with Ipamorelin, optionally combined with IGF-1 for localised, targeted growth.

Related products

CJC-1295 with DAC

CJC-1295 without DAC

Ipamorelin

For research use only. Not for human or veterinary use. Educational content; not medical advice.